Anesthetics cause a reduction in excitatory neurotransmission that may be important in the mechanisms of in vivo anesthetic action. Because glutamate is the major excitatory neurotransmitter in mammalian brain, evaluation of anesthetic effects on induced glutamate release is relevant for studying this potential mechanism of anesthetic action. In the present study, we compared the effects of anesthetics and nonanesthetics (halogenated alkanes that disobey the Meyer-Overton hypothesis) on depolarization-evoked glutamate release. Glutamate released from rat cortical brain slices after chemically induced depolarization (50 mM KCl) was measured continuously using an enzymatic fluorescence assay. The effects of the volatile anesthetics isoflurane and enflurane were compared with the effects of the transitional compound 1,1,2-trichlorotrifluoroethane, the nonanesthetic compound 1,2-dichlorohexafluorocyclobutane, and other polyhalogenated alkanes. Tested concentrations included effective anesthetic concentrations for the anesthetics and transitional compounds, and concentrations predicted to be anesthetic based on lipid solubility for the nonanesthetics. Isoflurane dose-dependently reduced depolarizationevoked glutamate release in cortical brain slices. Isoflurane and enflurane at concentrations equivalent to 1 minimum alveolar anesthetic concentration (MAC) reduced the KCl-evoked release to 20% and 17% of control, respectively.Thetransitionalcompound1,1,2-trichlorotrifluoroethane at 210 M (approximately 1.2 MAC) reduced glutamate release to 47%, and the nonanesthetic 1,2-dichlorohexafluorocyclobutane increased glutamate release at 70 M (approximately 3 MAC). These findings support the hypothesis that the modulation of excitatory neurotransmission might be responsible, in part, for in vivo anesthetic action. Implications: The volatile anesthetics isoflurane and enflurane reduce depolarizationevoked glutamate release in rat brain slices. The transitional compound 1,1,2-trichlorotrifluoroethane reduces glutamate release to a much lesser extent, and the nonanesthetic 1,2-dichlorohexafluorocyclobutane does not reduce glutamate release. These findings support the hypothesis that the modulation of excitatory neurotransmission might be responsible, in part, for in vivo anesthetic action.
Anesthetics cause a reduction in excitatory neurotransmission that may be important in the mechanisms of in vivo anesthetic action. Because glutamate is the major excitatory neurotransmitter in mammalian brain, evaluation of anesthetic effects on induced glutamate release is relevant for studying this potential mechanism of anesthetic action. In the present study, we compared the effects of anesthetics and nonanesthetics (halogenated alkanes that disobey the Meyer-Overton hypothesis) on depolarization-evoked glutamate release. Glutamate released from rat cortical brain slices after chemically induced depolarization (50 mM KCl) was measured continuously using an enzymatic fluorescence assay. The effects of the volatile anesthetics isoflurane and enflurane were compared with the effects of the transitional compound 1,1,2-trichlorotrifluoroethane, the nonanesthetic compound 1,2-dichlorohexafluorocyclobutane, and other polyhalogenated alkanes. Tested concentrations included effective anesthetic concentrations for the anesthetics and transitional compounds, and concentrations predicted to be anesthetic based on lipid solubility for the nonanesthetics. Isoflurane dose-dependently reduced depolarizationevoked glutamate release in cortical brain slices. Isoflurane and enflurane at concentrations equivalent to 1 minimum alveolar anesthetic concentration (MAC) reduced the KCl-evoked release to 20% and 17% of control, respectively.Thetransitionalcompound1,1,2-trichlorotrifluoroethane at 210 M (approximately 1.2 MAC) reduced glutamate release to 47%, and the nonanesthetic 1,2-dichlorohexafluorocyclobutane increased glutamate release at 70 M (approximately 3 MAC). These findings support the hypothesis that the modulation of excitatory neurotransmission might be responsible, in part, for in vivo anesthetic action. Implications: The volatile anesthetics isoflurane and enflurane reduce depolarizationevoked glutamate release in rat brain slices. The transitional compound 1,1,2-trichlorotrifluoroethane reduces glutamate release to a much lesser extent, and the nonanesthetic 1,2-dichlorohexafluorocyclobutane does not reduce glutamate release. These findings support the hypothesis that the modulation of excitatory neurotransmission might be responsible, in part, for in vivo anesthetic action.
(Anesth Analg 1999;88:1168 -74) S tudies of the mechanisms for producing in vivo anesthesia suggest that anesthetics may act on synaptic transmission rather than on axonal conduction (1). If anesthetics act by altering synaptic transmission, they may do so by inhibiting excitatory neurotransmission, enhancing inhibitory neurotransmission, or a combination of both actions (1-3). The Meyer-Overton hypothesis (lipid solubility correlates with anesthetic potency) indicates a main site of action for anesthetics that is hydrophobic, and a recent, widely supported interpretation postulates the action of anesthetics on proteins at binding sites that have hydrophobic properties (1, 4) . Several volatile drugs have been described that do not follow the MeyerOverton hypothesis, having either anesthetic potencies much lower than predicted by their lipid solubilities or no anesthetic effect as defined by minimum alveolar anesthetic concentration (MAC) (5-7). Because differences in lipid solubility do not explain the differences in anesthetic potency of drugs that disobey the Meyer-Overton hypothesis, they are useful instruments in the search for the site (or sites) and mechanisms of anesthetic action (8) .
Among these drugs are transitional compounds, so named because they produce anesthesia only at partial pressures higher than predicted by their lipid solubilities, and nonanesthetics, which lack any anesthetic (when tested alone) or additive (when tested with desflurane) properties (as defined by MAC), even at partial pressures several-fold greater than their predicted MAC (5, 9) . The nonanesthetics are now also known as "nonimmobilizers" (10) , based on studies that demonstrate that they do not abolish movement in response to noxious stimuli, but they do suppress learning, similar to anesthetics (11) .
Because inhibition of excitatory neurotransmission by suppression of glutamate release may be part of volatile anesthetic action in the central nervous system (12) , we compared the effects of isoflurane and enflurane with the effects of transitional compounds and nonanesthetic polyhalogenated alkanes on glutamate release after chemically induced depolarization.
Methods
All studies were approved by the University of California San Francisco Committee on Animal Research and conform to relevant National Institutes of Health guidelines.
The methods we applied for brain slice preparation have been previously described (13) . Brain slices were prepared from Sprague-Dawley rats aged 15-30 days. Rats were anesthetized with 1.5%-2% halothane in oxygen and killed by decapitation. The skull was then opened, and the brain hemispheres were quickly removed. Ice-cold (1-3°C) artificial cerebrospinal fluid (aCSF) (modified Earle's balanced salts, composition in mM: NaCl 116, NaHCO 3 25, KCl 5.4, CaCl 2 1.8, MgCl 2 0.9, NaH 2 PO 4 0.9, glucose 10, pH 7.40 bubbled with 95% O 2 /5% CO 2 ) was used for irrigation during dissection. The remaining steps of the preparation were performed in an ice-cold environment. The hemispheres were glued with cyanoacrylate to a holder and immersed in aCSF. Using a vibrating tissue slicer (Campden Instruments, Cambridge, UK), we prepared the slices (300 -350 m thick), then dissected out the cortex portions. Only cortex was used for the experiments. Slices were stored at room temperature (approximately 23°C) completely submersed in aCSF, bubbled with 95% O 2 /5% CO 2 . After 30 min, the solution in the vials was replaced with fresh aCSF, equilibrated with 95% O 2 /5% CO 2 . Slices were allowed to recover from slicing trauma for at least 45 min before experiments began.
Glutamate released from cortical slices during experiments was detected using a fluorescence assay in a Hitachi F-2000 fluorometer (Hitachi, Tokyo, Japan). Slices were mounted on a mesh screen and placed in a fluorometer cuvette containing aCSF prewarmed to 37°C, 1 mM nicotinamide adenine dinucleotide (NAD) (Sigma Chemical), and 6 IU/mL glutamate dehydrogenase (GDH) (Sigma Chemical). Saline (aCSF), saturated with the test compounds, and KCl were injected through a central hole in the lid covering the top of the cuvette, and a magnetic stirbar at the bottom of the cuvette ensured rapid mixing of the solutions.
Glutamate released from slices was converted to ␣-ketoglutarate with the reduction of NAD ϩ to NADH. The reaction, which is catalyzed by GDH, is:
The fluorescence from NADH was measured using an excitation wavelength of 340 nm and an emission wavelength of 460 nm. The measured fluorescence was plotted against the time, as shown in the sample recording ( Fig. 1) . The slopes of the resulting curves were graphically determined for the different phases of the experiments. After calibration of the assay, glutamate release rates were calculated from the slopes. Differences in calculated release rates before and after KCl exposure alone (control response), before and after exposure to test compounds alone (compoundevoked response), and before and after KCl exposure after pretreatment with test compounds (effect of test compounds on KCl-evoked response) were used to establish differences among compounds. In the treatment groups, the calculated rates were corrected for the differences in filling volumes of the cuvettes before and after exposure to the test compounds. Calibration of the assay was achieved by injecting l-glutamate (2-20 nmol) into a cuvette containing the same solution used for the cortical slice preparations (aCSF prewarmed to 37°C, 1 mM NAD, and 6 IU/mL GDH); the Arrows mark the time when either KCl or the compound was added to the cuvette. Evoked release is calculated from the difference between the slope before and after exposure to KCl or the compound. Position of the curves on the ordinate is arbitrary.
total volume in the cuvette was 2.0 mL. After completion of the enzymatic reaction, the total increase in fluorescence was measured and plotted against the glutamate concentration at the start of the reaction. The resulting calibration curve was used to calculate glutamate release rates from the measured slopes.
Test compounds were added to the experiments from saturated solutions of pure compound in aCSF to produce the desired final concentration of test compound in the cuvette. The saturated stock solutions were kept in gas-tight glass vials.
To exclude influences of the test compounds or KCl on the enzymatic assay, we conducted a series of trial experiments similar to the calibration experiments but with KCl and different test compounds added to the reaction. Neither KCl nor any of the tested drugs had an influence on the enzymatic reaction.
Time control studies showed stable recordings from slices, without any insult, of at least 15 min. In addition, the oxygen partial pressures in solutions identical to the cuvette solutions used for the studies were measured with an oxygen electrode (Cameron Instrument Co., Port Aransas, TX). The measured partial pressures were Ͼ200 mm Hg, even for mixtures containing an equivalent of 800 L of test compound. Previous studies of hypoxia-induced glutamate release have shown that oxygen partial pressure must be Ͻ50 mm Hg to trigger glutamate release (14) . All experiments were performed at 37°C. The aCSF solution was prewarmed, and a heating element attached to the cuvette holder was used to maintain this temperature throughout the experiment.
After placing the slice in the cuvette, glutamate release was followed until a stable release rate was achieved, indicated by a stable slope of the curve. At this point, data collection was started. Control response was defined as an increase in glutamate release evoked by 50 mM KCl in otherwise untreated brain slices. In these control experiments, KCl from a 3.0-M stock solution was injected into the cuvette to achieve a final concentration of 50 mM. In the treatment groups, the test compounds were added by syringe injection. The cuvette was covered with the holder for the slice, leaving just a small hole for syringe injection to minimize drug loss from solution. The experimental preparation was exposed to the test compound for approximately 3 min before cells were depolarized using KCl.
Results were calculated as picomoles of glutamate per milligram of protein per second. To estimate the protein content, brain slices were transferred to 50 mM HEPES buffer (pH 7.8) at 100°C and sonicated. The samples were stored at Ϫ80°C for later assay (Enhanced Protein Assay; Pierce, Rockford, IL).
The effect of the volatile anesthetics isoflurane and enflurane, the transitional compounds 1,1,2-trichlorotrifluoroethane and dibromodifluoromethane, and the nonanesthetics 1,2-dichlorohexafluorocyclobutane, 2,3-dichlorooctafluorobutane, and flurothyl were studied. The transitional compounds and nonanesthetics were chosen from the compounds evaluated by Koblin et al. (5) and were obtained from PCR, Inc. (Gainesville, FL).
Isoflurane was tested at four different concentrations (185, 370, 530, and 700 M) approximately equivalent to 0.5, 1, 1.5, and 2 MAC, respectively. The transitional compound 1,1,2-trichlorotrifluoroethane was tested at 90, 210, and 400 M, roughly equivalent to 0.5, 1.2, and 2.2 MAC, respectively. The nonanesthetic 1,2-dichlorohexafluorocyclobutane was tested at 10, 22, and 70 M, corresponding to 0.5, 1.2, and 3 times predicted MAC.
In addition, enflurane and three other halogenated alkanes were tested at single concentrations. The effect of enflurane was evaluated at 690 M (approximately 1 MAC). Dibromodifluoromethane, classified as a transitional compound because of its ability to reduce the MAC of desflurane (5), was tested at 1500 M, corresponding to approximately 1.5 times MAC. 2,3-Dichlorooctafluorobutane, a nonanesthetic drug as classified by Koblin et al. (5) , was tested at 1300 M, approximately equal to 2 times the predicted MAC. Flurothyl, a known potent convulsant (15), was examined at 290 M, a concentration roughly equal to 8 times the convulsive 50% effective dose (ED 50 ) and close to the concentration that had previously been discussed as the anesthetic ED 50 (approximately 10 times the convulsive ED 50 ) (15) .
In addition to the examined effects on KCl-evoked glutamate release, we also studied the basal glutamate release produced by anesthetics and nonanesthetics.
Trial experiments were performed to determine the actual concentrations of the test compounds present in the cuvette during the experiments. Samples of the solution were taken from the cuvette with a glass syringe at the start and the end of the experiments to measure partial pressure. The test compound was extracted into air in a constant temperature waterbath and injected into a Gow Mac gas chromatograph (Bridgewater, NJ) calibrated with the appropriate standards. From the difference between concentrations at the start and end of the experiments, the average loss was determined. The amounts of saturated solution added to the cuvettes were adjusted for the calculated loss, which ranged from 15% for isoflurane and enflurane to 37% for 1,2-dichlorohexafluorocyclobutane.
Results are reported as the mean Ϯ sd. n values correspond to the number of brain slices studied. The results were normalized relative to the mean release rate of the control experiments of that same day (mean control response). One-way analysis of variance (ANOVA) with Dunnett's test for post hoc comparisons was used to test for differences among the different concentrations and the control for each of the tested drugs. The effect of the test compounds on basal glutamate release was assessed using two-way ANOVA for repeated measures. P values Ͻ0.05 were considered to be statistically significant. Data were analyzed using Sigma Stat for Windows 2.0 (Jandel Corporation, San Rafael, CA).
Results
The mean depolarization-evoked glutamate release in control experiments, averaged from experiments over the entire study, was 5.30 Ϯ 3.11 pmol ⅐ mg Ϫ1 ⅐ s
Ϫ1
(n ϭ 28) (Fig. 1) . Isoflurane reduced depolarizationevoked glutamate release in a dose-dependent manner (Fig. 2) . At 370 M (approximately 1 MAC), isoflurane reduced glutamate release to 20% Ϯ 9% of the control response (P Ͻ 0.05).
The transitional compound 1,1,2-trichlorotrifluoroethane significantly reduced glutamate release to 73% Ϯ 37% and 47% Ϯ 20% of the control response at the two lower concentrations tested (90 M Ϸ 0.5 MAC and 210 M Ϸ 1 MAC, respectively) (Fig. 3) . This decrease was considerably smaller than that observed for isoflurane, and because no significant effect could be detected at 400 M (approximately 2 MAC), the observed effect of 1,1,2-trichlorotrifluoroethane does not follow a dose-response relationship similar to isoflurane.
In contrast, an increase of depolarization-evoked glutamate release was observed for the nonanesthetic 1,2-dichlorohexafluorocyclobutane at the highest tested concentration (70 M Ϸ 3 times the predicted MAC) (P Ͻ 0.05). The other tested concentrations (10 M and 22 M) did not have a significant effect on depolarization-evoked glutamate release (Fig. 4) .
Enflurane and three transitional or nonanesthetic alkanes were tested at single concentrations in the range of actual or predicted anesthetic concentrations. One MAC enflurane (690 M) reduced evoked release to 17% Ϯ 11%, comparable to the reduction caused by isoflurane. No effect on depolarization-evoked glutamate release was detected with the nonanesthetic 2,3-dichlorooctafluorobutane at a concentration equal to 2 times the predicted MAC (1300 M). The transitional compound dibromodifluoromethane and the nonanesthetic flurothyl showed a small to moderate effect: at 1500 M (approximately 1.5 MAC), dibromodifluoromethane showed a reduction to 63% Ϯ 38%, and flurothyl showed a reduction to 39% Ϯ 21% of KClevoked glutamate release (P Ͻ 0.05) at approximately 8 times the convulsive ED 50 (290 M). These results are summarized in Figure 5 .
In addition to the effect on KCl-evoked glutamate release, all anesthetic, transitional, and nonanesthetic compounds increased basal glutamate release per se in otherwise untreated brain slices (Fig. 1) . This druginduced increase of basal glutamate release was relatively small compared with the KCl-evoked glutamate release in otherwise untreated brain slices. For example, the increase of basal glutamate release produced by 0.5, 1, 1.5, and 2 MAC isoflurane was only 4.3% Ϯ Figure 2 . Isoflurane decreases depolarization-evoked glutamate (Glu) release from brain slices in a dose-dependent manner. The tested concentrations roughly correspond to 0.5, 1, 1.5, and 2 minimum alveolar anesthetic concentration, respectively. Depolarization was achieved by exposure to 50 mM KCl, which was injected into the fluorometer cuvettes. The results were normalized to the control response (exposure to 50 mM KCl of otherwise untreated slices). The bars represent mean Ϯ sd. n ϭ 7 for 530 M group, n ϭ 6 for all other groups. *Statistically significant difference from control experiments, analysis of variance with Dunnett's test (P Ͻ 0.05). 2.8%, 11.3% Ϯ 5.9%, 9.9% Ϯ 6.7%, and 23.4% Ϯ 11.3%, respectively, of the KCl-evoked glutamate release. The average increases for enflurane, the transitional compounds 1,1,2-trichlorotrifluoroethane and dibromodifluoromethane, and the nonanesthetic compounds 1,2-dichlorohexafluorocyclobutane, 2,3-dichlorooctafluroobutane, and flurothyl were 10.7% Ϯ 7.1%, 13.1% Ϯ 7.6%, 21.7% Ϯ 8.3%, 21.7% Ϯ 8.4%, 29.8% Ϯ 6.2%, and 17% Ϯ 5%, respectively, of the KCl-evoked glutamate release. There was no apparent correlation between the effects of the various compounds on basal glutamate release and their anesthetic or convulsive potencies.
Discussion
Our data demonstrate that anesthetics potently depress evoked glutamate release in cortical brain slices, whereas nonanesthetics do not. Transitional compounds reduce glutamate release to a much lesser extent. These results support the proposition that inhibition of excitatory neurotransmitter release might be important to in vivo anesthetic action.
Glutamate is probably the most important neurotransmitter for fast excitatory synaptic transmission in the mammalian brain (16, 17) . Various anesthetics reduce evoked transmitter release from brain slices and synaptosomes, which supports a hypothesis of anestheticinduced modulation of transmitter release (12,18 -21) . This hypothesis is further supported by the electrophysiologic findings of Perouansky et al. (3), who describe the reversible block of N-methyl-d-aspartate (NMDA) and non-NMDA excitatory postsynaptic currents caused by halothane at clinically relevant concentrations. Their findings can most likely be explained by inhibition of transmitter release. Glutamate uptake could be another possible target of anesthetic action, and a facilitation of the uptake mechanisms by anesthetics would also lower the effective neurotransmitter concentrations. Larsen et al. (22) report an isoflurane-induced facilitation of glutamate uptake in synaptosomes, an effect that would be synergistic with a presumed inhibition of transmitter release. However, reported facilitation of uptake was not evident at concentrations lower than 1%; at higher concentrations, it was too small to explain the 80% reduction in glutamate concentration observed in our study.
Our results show a clear difference in the effects of volatile anesthetics and nonanesthetics on KCl-evoked glutamate release. This is in contrast to the findings of Liachenko et al. (23) , who described a similar inhibition of glutamate release by the experimental anesthetic compound 1-chloro-1,2,2-trifluorocyclobutane and the nonanesthetic 1,2-dichlorohexafluorocyclobutane. However, these experiments were performed at a single concentration of only two compounds and did not include a comparison to a clinically used volatile anesthetic. Furthermore, the nonanesthetic compound (5), respectively. Depolarization was achieved by exposure to 50 mM KCl, which was injected into the fluorometer cuvettes. The results were normalized to the control response (exposure to 50 mM KCl of otherwise untreated slices). The bars represent mean Ϯ sd. n ϭ 5 for all groups. *Statistically significant difference from control experiments, analysis of variance with Dunnett's test (P Ͻ 0.05).
